WORCESTER, Mass., May 12, 2016 (GLOBE NEWSWIRE) -- Nemucore Medical Innovations, Inc., a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women’s cancers, today announced its poster presentation at American Congress of Obstetricians and Gynecologists (ACOG) Annual Clinical Meeting, May 16, 2016, in Washington DC at the Washington Convention Center. Nemucore will present a poster on its targeted platinum therapy NMI-350.
NMI-350 is a member of Nemucore’s NMI-300 family of less toxic platinum therapies. To improve pharmacodynamics of tumor interaction NMI-350 targets the folate receptor, which is expressed on 80% of ovarian cancers. NMI-350 is also an effective MRI contrast agent; it is annotated with a gadolinium chelate which allows MRI to be used to identify if NMI-350 is accumulating in tumors. Platinum based chemotherapy, introduced four decades ago, is a widely used cancer therapy and is still the standard of care for ovarian cancer. However dose limiting toxicities, cumulative dosing side effects, and the development of multidrug resistance eventually limit its effectiveness. NMI-350 is able to overcome drug resistance and shows improved efficacy compared to cisplatin with reduced off-target toxicity.
"Today physicians have limited tools to determine if a patient is resistant to platinum therapy, NMI-350 has the potential to disrupt this clinical inefficacy,” said Nemucore’s Chairman, CEO, & President Timothy Coleman, Ph.D. "Accumulation of NMI-350 in tumors can be tracked in real time ultimately improving patient care and outcomes. This data provides compelling evidence that molecularly targeted platinum theranostics can play a role in the care of patients with multidrug resistant cancers."
About Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women’s cancers. Nemucore's most advanced candidate NMI-900, a potential therapeutic for the treatment of ovarian cancer, is expected to begin a Phase 2b clinical trial in mid-2016. Two additional candidates are anticipated to enter clinical trial development later in 2016, targeting a variety of difficult-to-treat oncology indications, including triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other cancers. For more information, please visit our website at www.Nemucore.com.
CONTACT: Contacts: Tim Coleman (investors) Nemucore Medical Innovations (508) 762-1017 BCC Partners (media) Karen Bergman (650) 323-1717 firstname.lastname@example.org Jen LaVin (207) 360-0473 email@example.com